Signals, Powered By EquityPandit
Suven Life Sciences has secured 1 product patent from Europe and South Korea each, corresponding to the new chemical entities for the treatment of disorders associated with Neurodegenerative diseases.
These patents are valid through 2033 and 2034 respectively. The granted claims of the patents include the class of selective 5-HT4 and H3 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), etc.
Further, CEO of Suven Life Sciences, Venkat Jasti stated, “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”
